QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for analysis of genomic variants; and assays for prenatal testing and detection of sexually transmitted diseases and HPV; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers PCR consumables, such as quantitative PCR, reverse transcription and combinations kits for analysis of gene expression, genotyping and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. It offers predefined and custom NGS gene panels, library prep kits and components, whole genome amplification, etc.; bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company has collaboration agreements with Amgen Inc.; CLIA-certified laboratories; NuProbe Global; and Personal Genome Diagnostics Inc., as well as a strategic alliance agreement with Sysmex Corporation. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
IPO Year:
Exchange: NYSE
Website: qiagen.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/4/2025 | Buy → Neutral | Redburn Atlantic | |
| 2/19/2025 | $52.00 → $42.00 | Outperform → Neutral | Robert W. Baird |
| 1/6/2025 | $48.00 | Overweight → Equal-Weight | Morgan Stanley |
| 12/10/2024 | $42.50 → $54.00 | Hold → Buy | Jefferies |
| 10/17/2024 | $49.00 | Buy → Hold | HSBC Securities |
| 6/27/2024 | $50.00 | Peer Perform → Outperform | Wolfe Research |
| 12/19/2023 | $44.00 | Equal Weight | Wells Fargo |
| 12/13/2023 | Peer Perform | Wolfe Research | |
| 12/7/2023 | $50.00 | Neutral → Buy | Goldman |
| 9/12/2023 | $50.00 | Outperform | Robert W. Baird |
QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2025. Press release date / time: Wednesday, May 7, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, May 8, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect me Service is available 15 minutes before the call starts Dial-in by phone U.S.: +1 646 828 8193 UK: +44 (0)330 165 3655 GER: +49 (0)69 6610 2480 Conference ID: 5803222 To avoid waiting time, please join the event conference 5-10 minute
Q4 2024: Net sales of $521 million (+2% actual rates, +4% constant exchange rates (CER) core growth); diluted EPS of $0.39 and adjusted diluted EPS of $0.61 Net sales of $525 million CER ahead of outlook for at least $520 million CER and adjusted diluted EPS of $0.61 CER ahead of outlook for at least $0.60 CER QIAstat-Dx, QuantiFERON and QIAcuity digital PCR continue double-digit growth pace 30.6% adj. operating income margin up 2.6 percentage points vs. 28.0% in Q4 2023 FY 2024: Exceeded outlook for sales and adj. EPS; adj. operating income margin improves 1.8 percentage points to 28.7% Free cash flow rises 63% to $506 million 2025 outlook for about 4% CER sales grow
QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the fourth quarter 2024. Press release date / time: Wednesday, February 5, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, February 6, at 16:00 Frankfurt time / 15:00 London time / 10:00 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect me Service is available 15 minutes before the call starts Dial-in by phone U.S.: +1 646 828 8193 UK: +44 (0)330 165 4027 GER: +49 (0)69 6610 2480 Conference ID: 9237018 To avoid waiting time, please join the event confer
Venlo, the Netherlands, Nov. 06, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced results for the third quarter and first nine months of 2024. Net sales rose 5% to $502 million in Q3 2024 over Q3 2023, while results at constant exchanges rates (CER) of $502 million rose 6% and were above the outlook for at least $495 million CER. The adjusted operating income margin rose three percentage points to 29.6% on benefits from the recent decision to discontinue the NeuMoDx system as well as broader efficiency gains that have improved profitability and freed up resources for targeted reinvestment. Adjusted diluted earnings per share (EPS) were $0
Venlo, The Netherlands, Oct. 10, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the third quarter 2024. Press release date / time: Wednesday, November 6, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, November 7, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect meService is available 15 minutes before the call starts Dial-in by phone U.S.: +1 929 477 0448UK: +44 (0)330 165 3655GER: +49 (0)69 6610 2492Conference ID:
Highlights Second quarter revenue grew 15% year-over-year to $212 million, driven by Prenatal (25%), Pharmacogenomics (22%), and Hereditary Cancer (19%).Second quarter GAAP earnings per share improved to $(0.41) from $(1.42) in the second quarter of 2023; adjusted earnings per share improved to $0.05 from $(0.08) in the second quarter of 2023.Increasing 2024 financial guidance with full year revenue moving to a range of $835 - $845 million, or an annual growth rate of between 11% and 12%, and increasing adjusted earnings per share (EPS) to a range of $0.08 - $0.12.1 _________________________1 The company does not forecast GAAP EPS because it cannot predict certain elements that are include
Venlo, the Netherlands, July 31, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced results for the second quarter and first half of 2024. Net sales were stable at $496 million in Q2 2024 compared to Q2 2023, while results at constant exchanges rates (CER) of $502 million rose 1% and were above the outlook for at least $495 million CER. The adjusted operating income margin rose about one percentage point to 28.4% from Q2 2023 on efficiency gains while supporting targeted investments. Adjusted diluted earnings per share (EPS) were $0.55, and results at CER of $0.55 were above the outlook for at least $0.52 CER. QIAGEN has updated its FY
Venlo, The Netherlands, July 02, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the second quarter 2024. Press release date / time: Wednesday, July 31, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, August 1, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect meService is available 15 minutes before the call starts Dial-in by phone U.S.: +1 646 828 8193UK: +44 (0)330 165 3655GER: +49 (0)69 6610 2492Conference ID: 8081
Venlo, the Netherlands, April 29, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced results for the first quarter of 2024. Net sales declined 5% to $459 million, while results at constant exchanges rates (CER) of $462 million were above the outlook for at least $455 million CER. The adjusted operating income margin rose to 25.7% from 25.6% in the year-ago period on realized efficiency gains while supporting investments into the portfolio. Adjusted diluted earnings per share (EPS) were $0.46, and results at CER were $0.47 and above the outlook for at least $0.44 CER. For 2024, QIAGEN has reaffirmed its outlook for net sales of at least
Venlo, The Netherlands, April 09, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2024. Press release date / time: Monday, April 29, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Tuesday, April 30, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect meService is available 15 minutes before the call starts Dial-in by phone U.S.: +1 646 828 8193UK: +44 (0)330 165 3655GER: +49 (0)69 6610 2492Conference ID: 2903795To avoid
LANSING, Mich., Oct. 1, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today that it has appointed Thierry Bernard as a director to its Board, effective November 1, 2024. "We are pleased to welcome Thierry Bernard to the Neogen Board of Directors and look forward to his guidance as the company continues in its commitment to fueling a brighter future for global food security," said Jim Borel, Neogen's Board Chair. "As a sitting CEO with a wealth of knowledge in science and technologies relevant to Neogen and its
BERKELEY, Calif., Nov. 11, 2021 /PRNewswire/ -- Actym Therapeutics, Inc. today announced the appointment of Chan Whiting, Ph.D. as Chief Development Officer. Chan brings over 20 years of drug development experience within the biotechnology industry. As CDO, Chan will play a key leadership role in advancing Actym's pipeline of first-in-class, systemically administered therapeutics that re-program the immunosuppressive microenvironment in solid tumors. Actym Therapeutics hires Dr. Chan Whiting as Chief Development Officer."Chan has significant experience advancing novel cancer
JERSEY, Channel Islands, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced Mohammad El Khoury as the Company's Chief Commercial Officer. In this role, Mr. El Khoury will oversee all commercial activities for the company as it continues to expand globally. "I am delighted to welcome a strong and experienced commercial leader like Mohammad to the Executive team. During the last 30 years, he has been partnering with customers across the globe. Mohammad will be instrumental in accelerating the commercialization of our MosaiQ solution. He will continue to build the commercial team and expand the distribution channels whil
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today the appointment of Thomas Ebeling, a leading international executive with extensive experience in the healthcare, media and consumer goods industries, as a member of the Supervisory Board with immediate effect. Mr. Ebeling joins QIAGEN as part of a process launched by the Supervisory Board in 2020 to further complement and enhance the Board’s already extensive experience in Life Sciences and diagnostics. The addition of Mr. Ebeling brings the number of current Supervisory Board members to eight. “On behalf of the Supervisory Board and Managing Board, I would like to welcome Th
Three new innovative instrument launches expand reach into further lab segments and sample preparation customers as QIAGEN strengthens market-leading position QIAsymphony Connect set to start phased launch in 2025, first customer sessions being held to highlight enhanced capabilities for oncology and genomics workflows QIAsprint and QIAmini on track for 2026 launches, expanding options for high- and low-throughput lab demands QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced that plans are advancing to launch three new sample preparation instruments during 2025 and 2026 to expand and strengthen its portfolio for automated sample preparation. These systems are de
QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2025. Press release date / time: Wednesday, May 7, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, May 8, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect me Service is available 15 minutes before the call starts Dial-in by phone U.S.: +1 646 828 8193 UK: +44 (0)330 165 3655 GER: +49 (0)69 6610 2480 Conference ID: 5803222 To avoid waiting time, please join the event conference 5-10 minute
Q1 2025 preliminary net sales rise 7% CER and adjusted diluted EPS results of at least $0.55 CER both above outlook despite challenging macro environment Full-year 2025 adjusted diluted EPS outlook raised to about $2.35 CER (prior outlook about $2.28 CER) On track to exceed 31% CER adjusted operating income margin ahead of 2028 mid-term target QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced preliminary Q1 2025 results that exceeded its outlook for both net sales and adjusted earnings per share (EPS), reflecting strong performances across many growth drivers. Net sales grew approximately 5% (+7% at constant exchange rates, CER) to about $483 million in Q1 20
Malaria remains a major global health threat, with more than 250 million cases and 600,000 deaths in 2024 – over 90% of them in Africa QIAprep& Plasmodium Kit enables streamlined detection of five malaria-causing parasites for epidemiological research and surveillance Novel QIAGEN assays support mixed-infection tracking, vaccine impact assessment and malaria control strategies in regions with limited healthcare infrastructure QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced the launch of the QIAprep& Plasmodium Kit and two companion assays to support malaria research and surveillance efforts. This new solution combines sample preparation and quantitative
QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2024, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN's website here. QIAGEN will provide printed copies of the 2024 Annual Report to shareholders free of charge upon request. To obtain a printed copy of the 2024 Annual Report please use our contact form or send an email to [email protected]. About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extrac
New QIAstat-Dx Gastrointestinal Panel 2 Mini B adds to QIAGEN's growing U.S. menu for syndromic testing of gastrointestinal infections Panel delivers rapid detection of five common bacterial pathogens for outpatient use, aiding fast and informed treatment decisions QIAGEN building momentum in the U.S. syndromic testing market with six regulatory clearance of panels for use on QIAstat-Dx within the last 10 months QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use, further strengthening its syndromic testing portfolio in the United States. This
QIAGEN files lawsuit against bioMérieux with German Unified Patent Court to protect key innovations in its QuantiFERON technology QuantiFERON-TB Gold Plus plays a critical role in fighting the spread of TB worldwide QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced that it has filed a complaint against bioMérieux S.A. (EPA: BIM) for patent infringement, reinforcing its commitment to protecting the scientific advancements behind its proprietary QuantiFERON technology. The complaint, filed in the Local Division of the Court of First Instance of the Unified Patent Court (UPC) in Duesseldorf, Germany, concerns European Patent EP 2 276 883 B2. This patent, which i
New facility reflects QIAGEN's commitment to enhancing its bioinformatics data center infrastructure in the Australia, New Zealand, New Guinea and surrounding islands region New data center in Melbourne meets Australian regulations to ensure quality, scalable and trustworthy support for Omics analysis and interpretation in genomic testing labs Expands a QIAGEN network of seven data centers around the globe designed to ensure highest level of data security, compliance and operational excellence worldwide QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced the official opening of a new data center in Melbourne, Australia, designed to strengthen its global bioinf
Q4 2024: Net sales of $521 million (+2% actual rates, +4% constant exchange rates (CER) core growth); diluted EPS of $0.39 and adjusted diluted EPS of $0.61 Net sales of $525 million CER ahead of outlook for at least $520 million CER and adjusted diluted EPS of $0.61 CER ahead of outlook for at least $0.60 CER QIAstat-Dx, QuantiFERON and QIAcuity digital PCR continue double-digit growth pace 30.6% adj. operating income margin up 2.6 percentage points vs. 28.0% in Q4 2023 FY 2024: Exceeded outlook for sales and adj. EPS; adj. operating income margin improves 1.8 percentage points to 28.7% Free cash flow rises 63% to $506 million 2025 outlook for about 4% CER sales grow
QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced that the German Federal Patent Court (Bundespatentgericht) has ruled in its favor in a patent dispute against SD Biosensor, reaffirming the validity of an important patent protecting key innovations in its QuantiFERON technology. This ruling underscores the strength of QIAGEN's QuantiFERON intellectual property portfolio and protects the scientific advancements that have made QuantiFERON-TB Gold Plus the global standard for latent TB testing. "This decision involving an important patent for QuantiFERON reaffirms our ongoing commitment to delivering high-quality, science-driven solutions that improve health for patie
6-K - QIAGEN N.V. (0001015820) (Filer)
SCHEDULE 13G - QIAGEN N.V. (0001015820) (Subject)
6-K - QIAGEN N.V. (0001015820) (Filer)
6-K - QIAGEN N.V. (0001015820) (Filer)
6-K - QIAGEN N.V. (0001015820) (Filer)
6-K - QIAGEN N.V. (0001015820) (Filer)
6-K - QIAGEN N.V. (0001015820) (Filer)
6-K - QIAGEN N.V. (0001015820) (Filer)
6-K - QIAGEN N.V. (0001015820) (Filer)
6-K - QIAGEN N.V. (0001015820) (Filer)
Redburn Atlantic downgraded Qiagen from Buy to Neutral
Robert W. Baird downgraded Qiagen from Outperform to Neutral and set a new price target of $42.00 from $52.00 previously
Morgan Stanley downgraded Qiagen from Overweight to Equal-Weight and set a new price target of $48.00
Jefferies upgraded Qiagen from Hold to Buy and set a new price target of $54.00 from $42.50 previously
HSBC Securities downgraded Qiagen from Buy to Hold and set a new price target of $49.00
Wolfe Research upgraded Qiagen from Peer Perform to Outperform and set a new price target of $50.00
Wells Fargo initiated coverage of Qiagen with a rating of Equal Weight and set a new price target of $44.00
Wolfe Research initiated coverage of Qiagen with a rating of Peer Perform
Goldman upgraded Qiagen from Neutral to Buy and set a new price target of $50.00
Robert W. Baird initiated coverage of Qiagen with a rating of Outperform and set a new price target of $50.00
SC 13G - QIAGEN N.V. (0001015820) (Subject)
SC 13G/A - QIAGEN N.V. (0001015820) (Subject)
SC 13G/A - QIAGEN N.V. (0001015820) (Subject)
SC 13G/A - QIAGEN N.V. (0001015820) (Subject)
SC 13G/A - QIAGEN N.V. (0001015820) (Subject)
SC 13G/A - QIAGEN N.V. (0001015820) (Subject)
SC 13G/A - QIAGEN N.V. (0001015820) (Subject)